Spots Global Cancer Trial Database for An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
Official Title: 68Ga-PSMA-11 PET in Patients With Prostate Cancer
Study ID: NCT04777071
Study Description
Brief Summary: This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
Detailed Description: OUTLINE: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) then undergo PET/CT or PET/magnetic resonance (MR) scan over 2-4 minutes per bed position at baseline. Patients receiving systemic therapy undergo an additional 68Ga-PSMA-11 PET/CT or PET/MR scan 12 weeks after initiating therapy. Patients may also undergo CT and bone scan during screening. After the completion of study, patients are followed up at 60 days, 6 months, and annually up to 5 years or until time of first progression.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact Details
Name: Delphine L. Chen, M.D.
Affiliation: Fred Hutch/University of Washington Cancer Consortium
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
